Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
08 mai 2023 07h30 HE
|
Marker Therapeutics
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
01 mai 2023 07h30 HE
|
Marker Therapeutics
Structured To Extend Marker’s Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON, May 01, 2023 (GLOBE NEWSWIRE) --...
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
22 mars 2023 08h10 HE
|
Marker Therapeutics
2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia...
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
13 déc. 2022 07h00 HE
|
Marker Therapeutics
HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
22 nov. 2022 07h00 HE
|
Marker Therapeutics
HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
10 nov. 2022 16h05 HE
|
Marker Therapeutics
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
13 sept. 2022 07h00 HE
|
Marker Therapeutics
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
08 sept. 2022 07h00 HE
|
Marker Therapeutics
HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
11 août 2022 16h22 HE
|
Marker Therapeutics
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
04 août 2022 16h37 HE
|
Marker Therapeutics
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...